Directory
>
Mark Nuttall
Mark Nuttall
Vice President of Quality Assurance | Renibus Therapeutics Inc
Fort Worth, Texas, United States
Mark Nuttall
Summary
Mark Nuttall is an accomplished Vice President of Quality at Renibus Therapeutics, bringing over two decades of experience in quality assurance and analytical development within the pharmaceutical and biotechnology sectors. His career trajectory includes significant leadership roles at major organizations like AstraZeneca and Reckitt Benckiser, where he honed his expertise in managing quality systems and compliance. Mark's educational background in Biology from The University of Texas at Arlington laid the foundation for his scientific acumen and strategic thinking in quality management. He has a proven track record of enhancing operational efficiencies and driving quality improvements across various organizations. Mark is passionate about fostering innovation in quality assurance practices and is committed to advancing therapeutic solutions that positively impact patient care. His extensive experience in both corporate and startup environments equips him with a unique perspective on navigating the complexities of the healthcare landscape. Mark's dedication to quality and excellence is evident in his leadership style and professional achievements.
Mark Nuttall
Work Experience
Vice President of Quality Assurance at
Renibus Therapeutics Inc
January 2017 - Present
Vice President of Quality Assurance at
AstraZeneca
January 2015 - January 2017
Vice President of Quality Assurance at
ZS Pharma, Inc.
January 2012 - January 2015
Analytical Development Manager at
RECKITT BENCKISER GROUP PLC
January 2007 - January 2012
Director of Analytical Development at
Adam'S Respiratory Therapeutics
January 2004 - January 2007
Laboratory Supervisor at
ADAMS LABORATORIES
January 1992 - January 2004
Mark Nuttall
Education
The University of Texas at Arlington, B.S.
January 1987 - January 1992
Frequently Asked Questions about Mark Nuttall
What is Mark Nuttall email address?
Mark Nuttall's primary email address is ************@spie.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Mark Nuttall work for?
Mark Nuttall is a Vice President of Quality Assurance at Renibus Therapeutics Inc, a company specializing in Commercial physical research.
Where Mark Nuttall graduated from?
Mark Nuttall holds a degree in Biology from The University of Texas at Arlington.
How can I directly contact Mark Nuttall?
To contact Mark Nuttall directly, you can use the email address ************@spie.com. Complete contact information is available upon registration with Muraena.
Who is Mark Nuttall?
Mark Nuttall is an accomplished Vice President of Quality at Renibus Therapeutics, bringing over two decades of experience in quality assurance and analytical development within the pharmaceutical and biotechnology sectors. His career trajectory includes significant leadership roles at major organizations like AstraZeneca and Reckitt Benckiser, where he honed his expertise in managing quality systems and compliance. Mark's educational background in Biology from The University of Texas at Arlington laid the foundation for his scientific acumen and strategic thinking in quality management. He has a proven track record of enhancing operational efficiencies and driving quality improvements across various organizations. Mark is passionate about fostering innovation in quality assurance practices and is committed to advancing therapeutic solutions that positively impact patient care. His extensive experience in both corporate and startup environments equips him with a unique perspective on navigating the complexities of the healthcare landscape. Mark's dedication to quality and excellence is evident in his leadership style and professional achievements.
Mark`s contact details
************@spie.com
********@renibus.com
Colleagues
Vice President, Clinical Development
Vice President Program Management
Vice President of Medical Affairs
Vice President Clinical Operations
Chief Financial Officer
President and CEO Renibus Therapeutics